• Core testing revenue up 92% year-on-year and volume up 78%
• Key enterprise accounts growing in Australia
• On track to launch new GI Navigator testing product in September
• Cost reduction program on track
• Therapeutic partnering active

Microba Life Sciences Ltd reported a successful Q4 FY26, with core testing revenue up 92% and core testing volume up 78% year-on-year. Key highlights include the growth of key enterprise accounts in Australia, the on-track launch of the new GI Navigator testing product in September, and the progress of the cost reduction program. The company also attended the 2026 BIO International Convention and hosted partnering meetings in preparation for a formal partnering campaign. Financial performance showed Q4 FY26 cash receipts of $3.95m, total revenue of $4.07m, and FY26 total revenue of $14.78m. The company completed a $5.0m placement to fund the path to cashflow break-even.

FY26 total revenue $14.78m, down 6% YoY; core testing revenue grew 92% YoY

Microba is on track to launch GI Navigator in September, with a new revenue base and a focused core testing business. The company is also focused on delivering the whole company to cashflow break-even.